CYP2B6 and neuroblastoma: The major aim of the present study was to determine the role of CYP2B6 pharmacogenetic variability and patient-specific phenoconverting factors, such as age and sex, in the development of toxic events in pediatric patients with neuroblastoma undergoing cyclophosphamide therapy.